Abstract:Intravenous thrombolytic therapy in acute ischemic stroke patients is complicated by intracerebral hemorrhage (ICH) at a site remote from the infarcted area in roughly 2–3% of cases (1, 2). Historically, the etiology underlying these was proposed to be hemorrhagic infarction at a distant unrecognized silent focus of ischemia from multiple emboli. However, the use of diffusion-weighted imaging has demonstrated clear examples of remote intracerebral hemorrhage (rICH) occurring at sites devoid of ischemia, signifying alternate contributory mechanisms (3). Cerebral microbleeds (CMBs) are markers of bleeding-prone microangiopathies – most commonly hypertensive arteriopathy and cerebral amyloid angiopathy (CAA) (4) – that are visualized on T2*-weighted magnetic resonance imaging (MRI). Pathological studies have demonstrated intact erythrocytes underlying 13% of CMBs (5) implying that a subset of these lesions reflect acute or subacute areas of microhemorrhage. Fittingly, radiographic studies have demonstrated development of new CMBs in 5–13% of acute ischemic stroke patients within the first week after symptom onset (6–8). It is hence biologically plausible that thrombolysis-induced expansion of rapidly appearing CMBs might be the cause underlying a proportion of rICH in acute ischemic stroke patients. In this Opinion piece, we explored this hypothesis by pooling available evidence from relevant MRI patient cohorts with acute ischemic stroke. Two recent studies from east-Asian centers including a total of 345 patients have assessed the risk of rICH in patients who develop new post-stroke CMBs. Both studies used exclusively intravenous thrombolysis with rtPA: the dose used was 0.6 mg/kg in one study (7) and 0.9 mg/kg in the other (8). Overall, 129 (39%) of the patients had CMBs on pre-treatment baseline MRI and 17 (5%) developed new CMBs at 24 h post-thrombolysis. Post-thrombolysis rICH occurred in 2% (n = 7) of the entire population. In fixed effects pooled meta-analysis of the data, patients who developed new CMBs had a significantly increased risk of rICH than patients without new CMBs (odds ratio (OR) 16.15, 95% CI 3.72–70.18, p < 0.0001; Figure Figure1).1). The results were consistent in sensitivity analysis using a random effects model. Figure 1 New cerebral microbleeds and remote (i.e., extra-ischemic) intracerebral hemorrhage. Meta-analysis of the association between symptomatic remote intracerebral hemorrhage (ICH) risk in patients with acute ischemic stroke treated with intravenous thrombolysis, ... These findings, although preliminary, suggest that thrombolysis-induced expansion of new CMBs might account for a proportion of rICH in acute ischemic stroke patients. Post-thrombolysis rICH has been previously documented to occur at a site of CMB (9) and meta-analyses have suggested elevated risk of any post-thrombolysis symptomatic intracerebral hemorrhage in patients with CMBs (10, 11). However, whether these lesions – detected on baseline pre-thrombolysis MRI – were acute CMBs or simply a chronic marker of underlying hemorrhage-prone microangiopathies in the brain is uncertain, as thus far only chronic-subacute CMBs have been proposed to possibly have a distinctive MRI signature (12). Two cohorts published in the last year have attempted to characterize clinical predictors of rICH (1, 2). In the Safe Implementation of Treatments in Stroke-International Stroke Register (SITS-ISTR) prior stroke and older age were independently associated with rICH. However, the lack of robust associations with traditional ischemic risk factors led the authors to postulate whether another undetected mechanism, including CAA (13), was at play (2). Conversely, prior transient ischemic attack (TIA) was the only clinical predictor of rICH in an Australian cohort (1). Although, this observation could support the notion that rICH occurs from hemorrhagic transformation of unrecognized acute or subacute ischemic infarcts, patients with CAA often experience transient focal neurological episodes that can mimic TIA, and are highly predictive of future lobar ICH (14). Together, these observations raise the possibility that multiple etiologies (both primary hemorrhagic and primary ischemic) likely contribute to the pathogenesis of post-thrombolysis rICH. They also demonstrate the rapidly evolving nature of microbleeds in the acute phase of ischemic stroke, suggesting a potential role of an active small vessel microangiopathic process (15). As our pooled analysis is unadjusted, it remains to be determined whether the association between new CMBs and rICH is indeed an independent one or rather simply an indirect association due to common underlying pathophysiology, such as small vessel disease, stroke-induced acute hypertensive response, or neurovascular unit dysfunction from up regulation of inflammatory cascades. Future larger studies that incorporate a comprehensive assessment of both clinical and MRI predictors of rICH, as well as circulating markers of inflammation, would further elucidate this hypothesis.

Rapid breakdown of microvascular barriers and subsequent hemorrhagic transformation after delayed recombinant tissue plasminogen activator treatment in a rat embolic stroke model

Magnetic Resonance Perfusion Parameter to Predict Hemorrhagic Transformation after Intravenous Thrombolysis

Multi-mode MRI-based Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator(rtpa)reduces Hemorrhagic Transformation in Ischemic Stroke Patients

New microbleeds after thrombolysis: contiguous thin-slice 3T MRI.

New Cerebral Microbleeds and Mechanism of Post-Thrombolysis Remote Intracerebral Hemorrhage: “red Meets White” Revisited†

The Relationship Between T2 White-Matter Hyperintensities and Hemorrhagic Transformation and Neurological Outcome after Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke

Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion

tPA Mobilizes Immune Cells that Exacerbate Hemorrhagic Transformation in Stroke

Neutrophil migration participates in the side effect of recombinant human tissue plasminogen activator

Early Ischemic Blood Brain Barrier Damage: A Potential Indicator for Hemorrhagic Transformation Following Tissue Plasminogen Activator (tpa) Thrombolysis?

Effects of Rt-Pa Intravenous Thrombolysis on Blood-Brain Barrier Permeability, the Expressions and the Activities of MMP-2 and MMP-9 after Cerebral Ischemia in Rats

A modified rat model of thromboembolism for study of hemorrhagic transformation in stroke after intrave-nous thrombolysis

A Canine Model of Hemorrhagic Transformation Using Recombinant Tissue Plasminogen Activator Administration after Acute Ischemic Stroke

Microbleeds, Cerebral Hemorrhage, and Functional Outcome After Stroke Thrombolysis.

Magnetic Resonance Imaging Characterization Of Hemorrhagic Transformation Of Embolic Stroke In The Rat

Abstract WP312: Rosiglitazone Ameliorates Tissue Plasminogen Activator-Induced Hemorrhagic Transformation after Stroke Via Promoting Phagocytic Activity of Microglia

Systemic Thrombolysis With Recombinant Tissue Plasminogen Activator and Tirofiban in Acute Middle Cerebral Artery Occlusion

Timing of recanalization and outcome in ischemic-stroke patients treated with recombinant tissue plasminogen activator.

Prediction of Reperfusion-Associated Hemorrhagic Transformation Using Dynamic Contrast-Enhanced Imaging in A Rat Stroke Model

The Mechanism of Hemorrhagic Transformation in a Rat Cerebral Infarction Model Embolized by Autologous Blood Clot

Reocclusion and Hemorrhagic Transformation following Thrombolytic Therapy